Systemic administration of immune checkpoint inhibitors targeting programmed cell death protein 1 (PD1)/programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA4) co-inhibitory pathway improves overall survival in patients with metastatic tumors.1 Here, PDCD1 is linked to metastatic neoplasm.